Skip to main content
Erschienen in: Medical Oncology 3/2011

01.09.2011 | Original Paper

Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer

verfasst von: Xue-Qin Yang, Yan Li, Chuang Chen, Chun-Wei Peng, Shao-ping Liu, Yang Liu

Erschienen in: Medical Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

To evaluate the prognostic value of preoperative serum carbohydrate antigen19-9 (CA19-9), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125) for overall survival (OS) in patients with colorectal cancer (CRC). Preoperative serum CA19-9, CEA, and CA125 levels were detected by C12 protein chip diagnostic system in 80 patients with CRC, and the association of their preoperative status with the patients’ OS was analyzed. Patients with positive preoperative serum CA19-9, CA125, and CEA had a worse survival comparing with those negative patients, the difference in CA19-9 and CA125 reached statistical significance (Log rank test, P < 0.05), but the difference of CEA did not achieve statistical significance (Log rank test, P > 0.05). The OS of patients with CRC with three positive tumor markers (TMs) <1 or 2 positive TMs < negative TM, simultaneously positive serum CA19-9, CEA, and CA125 was the most dismal predicting factor for OS. Spearman correlations revealed that the preoperative serum status of CA19-9 (P = 0.000), CEA (P = 0.000), and CA125 (P = 0.000) had correlations with stage; the preoperative serum CA125 status (r = −0.385, P = 0.000) and stage (r = −0.457, P = 0.000) and location (r = 0.223, P = 0.047) had correlations with OS. Multivariate analysis with Cox regression model showed that only stage (P = 0.000) and the preoperative serum CA125 status (P = 0.016) were independent prognostic factors for OS of patients with CRC. The preoperative status of serum CA19-9, CEA, and CA125 had correlations with CRC stage. The simultaneously positive serum CA19-9, CEA, and CA125 was the most dismal predicting factor for OS of patients with CRC. Preoperative serum CA125 status and stage were independent prognostic factors for OS of CRC.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef
2.
Zurück zum Zitat Zheng S. Prevention of colorectal carcinoma. Chin J Cancer Prev Treat. 2006;13(1):1–2. Zheng S. Prevention of colorectal carcinoma. Chin J Cancer Prev Treat. 2006;13(1):1–2.
4.
Zurück zum Zitat Yang XQ, Yan L, Chen C, Hou JX, Li Y. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement. Hepatogastroenterol. 2009;56(94–95):1388–94. Yang XQ, Yan L, Chen C, Hou JX, Li Y. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement. Hepatogastroenterol. 2009;56(94–95):1388–94.
5.
Zurück zum Zitat Tang R, Yeh CY, Wang JY, Changchien CR, Chen JS, Hsieh LL. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol. 2009;16(9):2516–23.PubMedCrossRef Tang R, Yeh CY, Wang JY, Changchien CR, Chen JS, Hsieh LL. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol. 2009;16(9):2516–23.PubMedCrossRef
6.
Zurück zum Zitat Sun LC, Chu KS, Cheng SC, Lu CY, Kuo CH, Hsieh JS, et al. Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer. 2009;9(1):288–95.PubMedCrossRef Sun LC, Chu KS, Cheng SC, Lu CY, Kuo CH, Hsieh JS, et al. Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer. 2009;9(1):288–95.PubMedCrossRef
7.
Zurück zum Zitat Holten-Andersen MN, Fenger C, Nielsen HJ, Rasmussen AS, Christensen IJ, Brünner N, et al. Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer. 2004;40(14):2159–64.PubMedCrossRef Holten-Andersen MN, Fenger C, Nielsen HJ, Rasmussen AS, Christensen IJ, Brünner N, et al. Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer. 2004;40(14):2159–64.PubMedCrossRef
8.
Zurück zum Zitat Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brünner N, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. A validation study. Eur J Cancer. 2004;40(1):64–72.PubMedCrossRef Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brünner N, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. A validation study. Eur J Cancer. 2004;40(1):64–72.PubMedCrossRef
9.
Zurück zum Zitat Mroczko B, Groblewska M, Wereszczyńska-Siemiatkowska U, Okulczyk B, Kedra B, Łaszewicz W, et al. Serum macrophagecolony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta. 2007;380(1–2):208–12.PubMedCrossRef Mroczko B, Groblewska M, Wereszczyńska-Siemiatkowska U, Okulczyk B, Kedra B, Łaszewicz W, et al. Serum macrophagecolony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta. 2007;380(1–2):208–12.PubMedCrossRef
10.
Zurück zum Zitat Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267–77.PubMedCrossRef Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267–77.PubMedCrossRef
11.
Zurück zum Zitat Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, et al. Soluble epidermal growth factor receptor (SEG-FR) and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(2):306–18.PubMedCrossRef Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, et al. Soluble epidermal growth factor receptor (SEG-FR) and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(2):306–18.PubMedCrossRef
12.
Zurück zum Zitat Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10(2):150–4.PubMedCrossRef Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10(2):150–4.PubMedCrossRef
13.
Zurück zum Zitat Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum. 2004;47(2):227–32.PubMedCrossRef Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum. 2004;47(2):227–32.PubMedCrossRef
14.
Zurück zum Zitat Papk IJ, Choi GS, Jun SH. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res. 2009;29(10):4303–8. Papk IJ, Choi GS, Jun SH. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res. 2009;29(10):4303–8.
15.
Zurück zum Zitat Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol. 2009;16(11):3087–93.PubMedCrossRef Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol. 2009;16(11):3087–93.PubMedCrossRef
16.
Zurück zum Zitat Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47(4):624–30.PubMed Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47(4):624–30.PubMed
17.
Zurück zum Zitat Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23(4):338–51.PubMed Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23(4):338–51.PubMed
18.
Zurück zum Zitat Rodríguez-Moranta F, Saló J, Arcusa A, Boadas J, Piñol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24(3):386–93.PubMedCrossRef Rodríguez-Moranta F, Saló J, Arcusa A, Boadas J, Piñol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24(3):386–93.PubMedCrossRef
19.
Zurück zum Zitat Wang JY, Wu CH, Lu CY, Hsieh JS, Wu DC, Huang SY, et al. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis. World J Surg. 2006;30(6):1007–13.PubMedCrossRef Wang JY, Wu CH, Lu CY, Hsieh JS, Wu DC, Huang SY, et al. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis. World J Surg. 2006;30(6):1007–13.PubMedCrossRef
20.
Zurück zum Zitat Li PC, Chen LD, Zheng F, Li Y. Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study. J Cancer Res Clin Oncol. 2008;134(1):37–44.PubMedCrossRef Li PC, Chen LD, Zheng F, Li Y. Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study. J Cancer Res Clin Oncol. 2008;134(1):37–44.PubMedCrossRef
21.
Zurück zum Zitat Al-Shammaa HAH, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008;14(8):1159–66.PubMedCrossRef Al-Shammaa HAH, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008;14(8):1159–66.PubMedCrossRef
22.
Zurück zum Zitat Yang XJ, Li Y, Al-shammaa HAH, Yang GL, Liu SY, Lu YL, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol. 2009;16(2):345–51.PubMedCrossRef Yang XJ, Li Y, Al-shammaa HAH, Yang GL, Liu SY, Lu YL, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol. 2009;16(2):345–51.PubMedCrossRef
Metadaten
Titel
Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer
verfasst von
Xue-Qin Yang
Yan Li
Chuang Chen
Chun-Wei Peng
Shao-ping Liu
Yang Liu
Publikationsdatum
01.09.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9518-z

Weitere Artikel der Ausgabe 3/2011

Medical Oncology 3/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.